ERBB2 and cancer: In addition, HER2 mutations in HER2-positive cancers were more likely to occur in ECD (44.2% vs. 25.0%), whereas the mutations that occurred in HER2-negative cancers were more likely to occur in the kinase domain (25.8% vs. 57.7%).